Author:
Wiedmann Marcus,Witzigmann Helmut,Mössner Joachim
Publisher
Springer Berlin Heidelberg
Reference435 articles.
1. Abid L, Oukkal M, Berkane S, et al (2003) Phase II trial with the gemcitabine and cisplatin combination in the treatment of locally advanced and metastatic gall bladder carcinoma. Proc ASCO (abstract 1302)
2. Abou-Alfa GK, Rowinsky EK, Patt YZ, et al (2005) A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers. Am J Clin Oncol 28: 334–9
3. Adamek HE, Albert J, Weitz M, et al (1998) A prospective evaluation of magnetic resonance cholangiopancreatography in patients with suspected bile duct obstruction. Gut 43: 680–3
4. Adjei AA, Erlichman C, Sloan JA, et al (2000) Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol 18: 1748–57
5. Ahrendt SA, Eisenberger CF, Yip L, et al (1999) Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis-associated cholangiocarcinoma. J Surg Res 84: 88–93